Bluejay Diagnostics Reports 2022 Financial Results
March 20, 2023 16:15 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its...
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
February 16, 2023 08:00 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass. and WEST WARWICK, R.I., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have...
Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
November 09, 2022 08:00 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient...
Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 16:05 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid,...
Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure
August 16, 2022 07:30 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid,...
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
July 27, 2022 07:30 ET
|
Bluejay Diagnostics, Inc.
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of...
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
July 26, 2022 16:30 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid,...
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
July 06, 2022 07:30 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid,...
Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
June 09, 2022 07:30 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid,...
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
April 20, 2022 16:10 ET
|
Bluejay Diagnostics, Inc.
ACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective,...